Medicis Announces Approval Of Additional Strengths Of Solodyn(R)

Medicis (NYSE:MRX) announced that the U.S. Food and Drug Administration (FDA) has approved additional strengths of SOLODYN(R) (minocycline HCl, USP) Extended Release Tablets in 55 mg, 80 mg and 105 mg dosages for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older

Read the original post:
Medicis Announces Approval Of Additional Strengths Of Solodyn(R)

Related posts:

1. Medicis Announces Approval of New Strengths of SOLODYN(R) SCOTTSDALE, Ariz., July 27, 2009 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX)...
2. Onset Therapeutics Announces Results Of BenzEFoam™ Skin Hydration Study Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, today...
3. Elorac, Inc. Announces Clinical Results Of Carbamide Peroxide Studies For The Treatment Of Acne Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on...
4. XOMA Initiates Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris BERKELEY, Calif., Dec. 21, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd....
5. Solta to buy ultrasound fat treatment company from Medicis Solta Medical Inc. will buy all of the outstanding shares...

Leave a comment

Name (required)

E-mail (required)

URI

Your Message